Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

doi:10.1038/s41569-020-0339-2

科研成果详情

题名	Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence
作者	Tan, Yi 1,2,3; Zhang, Zhiguo 4; Zheng, Chao5; Wintergerst, Kupper A.1,2,6; Keller, Bradley B.3,7; Cai, Lu 1,2,3,8
发表日期	2020-09
发表期刊	NATURE REVIEWS CARDIOLOGY 影响因子和分区
语种	英语
原始文献类型	Review
其他关键词	VENTRICULAR DIASTOLIC DYSFUNCTION ; PRESERVED EJECTION FRACTION ; RAT CARDIAC MYOCYTES ; HIGH-FAT DIET ; NF-KAPPA-B ; INHIBITING NLRP3 INFLAMMASOME ; CARDIOVASCULAR-DISEASE RISK ; TO-MESENCHYMAL TRANSITION ; INCIDENT HEART-FAILURE ; GLYCATION END-PRODUCTS
摘要	The pathogenesis and clinical features of diabetic cardiomyopathy have been well-studied in the past decade, but effective approaches to prevent and treat this disease are limited. Diabetic cardiomyopathy occurs as a result of the dysregulated glucose and lipid metabolism associated with diabetes mellitus, which leads to increased oxidative stress and the activation of multiple inflammatory pathways that mediate cellular and extracellular injury, pathological cardiac remodelling, and diastolic and systolic dysfunction. Preclinical studies in animal models of diabetes have identified multiple intracellular pathways involved in the pathogenesis of diabetic cardiomyopathy and potential cardioprotective strategies to prevent and treat the disease, including antifibrotic agents, anti-inflammatory agents and antioxidants. Some of these interventions have been tested in clinical trials and have shown favourable initial results. In this Review, we discuss the mechanisms underlying the development of diabetic cardiomyopathy and heart failure in type 1 and type 2 diabetes mellitus, and we summarize the evidence from preclinical and clinical studies that might provide guidance for the development of targeted strategies. We also highlight some of the novel pharmacological therapeutic strategies for the treatment and prevention of diabetic cardiomyopathy. Diabetic cardiomyopathy occurs as a result of the dysregulated glucose and lipid metabolism, increased oxidative stress and activation of pro-inflammatory pathways associated with diabetes mellitus, which can induce cardiac remodelling and dysfunction. In this Review, Tan and colleagues discuss the pathogenesis of diabetic cardiomyopathy and describe signalling pathways that might be potential therapeutic targets.
资助项目	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01-HL-125877-01]; American Diabetes AssociationAmerican Diabetes Association [1-15-BS-018, 1-18-IBS-082, 1-13-JF-53]; UofL-China Paediatric Research Exchange Program at the University of Louisville, USA; Norton Children's Hospital Foundation & Norton Healthcare Foundation
出版者	NATURE RESEARCH
出版地	BERLIN
ISSN	1759-5002
EISSN	1759-5010
卷号	17 期号:9 页码:585-607
DOI	10.1038/s41569-020-0339-2
页数	23
WOS类目	Cardiac & Cardiovascular Systems
WOS研究方向	Cardiovascular System & Cardiology
WOS记录号	WOS:000514761100001
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	32080423
PMC记录号	PMC7849055
SCOPUSEID	2-s2.0-85079773506
ESI高被引论文	2021-01 ; 2021-03 ; 2021-05 ; 2021-07 ; 2021-11 ; 2022-01 ; 2022-03 ; 2022-07 ; 2022-09 ; 2022-11 ; 2023-01 ; 2023-03 ; 2023-05 ; 2023-07 ; 2023-09 ; 2023-11 ; 2024-01 ; 2024-03 ; 2024-05 ; 2024-07 ; 2024-09 ; 2024-11
自科自定义期刊分类	T3(A)类
通讯作者地址	[Tan, Yi]Pediatric Research Institute,Department of Pediatrics,University of Louisville School of Medicine,Louisville,United States ; [Cai, Lu]Pediatric Research Institute,Department of Pediatrics,University of Louisville School of Medicine,Louisville,United States
Scopus学科分类	Cardiology and Cardiovascular Medicine
TOP期刊	TOP期刊
引用统计	被引频次：186[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/6647
专题	第二临床医学院，附属第二医院、育英儿童医院附属第二医院
通讯作者	Tan, Yi; Cai, Lu
作者单位	1.Pediatric Research Institute,Department of Pediatrics,University of Louisville School of Medicine,Louisville,United States; 2.Wendy Novak Diabetes Center,University of Louisville,Norton Children’s Hospital,Louisville,United States; 3.Department of Pharmacology and Toxicology,University of Louisville School of Medicine,Louisville,United States; 4.Department of Cardiology,The First Hospital of Jilin University,Changchun,China; 5.The Second Affiliated Hospital Center of Chinese–American Research Institute for Diabetic Complications,The Second Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 6.Division of Endocrinology,Department of Pediatrics,University of Louisville School of Medicine,Louisville,United States; 7.Kosair Charities Pediatric Heart Research Program,Cardiovascular Innovation Institute,University of Louisville,Louisville,United States; 8.Department of Radiation Oncology,University of Louisville School of Medicine,Louisville,United States
推荐引用方式 GB/T 7714	Tan, Yi,Zhang, Zhiguo,Zheng, Chao,et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence[J]. NATURE REVIEWS CARDIOLOGY,2020,17(9):585-607.
APA	Tan, Yi, Zhang, Zhiguo, Zheng, Chao, Wintergerst, Kupper A., Keller, Bradley B., & Cai, Lu. (2020). Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. NATURE REVIEWS CARDIOLOGY, 17(9), 585-607.
MLA	Tan, Yi,et al."Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence".NATURE REVIEWS CARDIOLOGY 17.9(2020):585-607.